Contents
Net sales
Operating income
Ordinary income
Net income
Net assets
Total net assets
Return on equity [ROE]
Total shareholders’ equity ratio
Net income per share [EPS]
Book value per share [BPS]
Dividend per share
Consolidated payout ratio
Dividend on equity [DOE]
Business Segment
New ethical drugs, etc. (Japan)
New ethical drugs(Overseas)
Generic drugs
Main Products
Flutiform
Desalex
Beova
Lasvic
Pentasa
Uritos
Nasonex
Kipres
Mucodyne
Montelukast “KM”
Mometasone “KYORIN”
Imidafenacin “KYORIN”
Net cash provided by operating activities
Net cash used in investing activities
Net cash used in financing activities
Cash and cash equivalents at end of year
R&D expenses
Capital expenditure
Depreciation and amortization
